Shingrix is a vaccine used in adults aged 50 years and over to protect against shingles (herpes zoster) and post-herpetic neuralgia (long-lasting nerve pain following shingles). It can also be used from the age of 18 years and over in adults who are at increased risk of herpes zoster. Shingles is a painful, blistering rash caused by the reactivation of the virus that causes chickenpox. After a patient has had chickenpox, the virus can lie dormant in the nerves and become active again if the immune system (the body’s natural defences) weakens due, for example, to ageing or to an illness. Shingrix contains a protein (glycoprotein E) from varicella zoster virus, the virus that causes chickenpox.
Therapeutic Indication
### Therapeutic indication Shingrix is indicated for prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN), in: - adults 50 years of age or older; - adults 18 years of age or older at increased risk of HZ. The use of Shingrix should be in accordance with official recommendations.
Therapeutic Area (MeSH)
ATC Code
J07BK03
ATC Item
zoster, purified antigen
Pharmacotherapeutic Group
Vaccines
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| recombinant varicella zoster virus glycoprotein E | N/A | Varicella zoster vaccine (recombinant) |
EMA Name
Shingrix
Medicine Name
Shingrix
Aliases
N/A
